NEW HAVEN, Conn., Sept. 4 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a
development-stage company focused on the discovery, development and
commercialization of novel antibiotics for the treatment of acute care
antibiotic-resistant infections, announced today that Thomas R. Kassberg has
joined the company as Chief Business Officer. In his new role, Mr. Kassberg
will lead the company's business development activities.
